Answer
Darunavir in Rezolsta inhibits HIV-1 protease dimerisation and catalytic activity, selectively blocking cleavage of HIV-encoded Gag-Pol polyproteins in infected cells and thereby preventing formation of mature infectious virus particles.
Sources for this answer
- REZOLSTA 800 mg/150 mg film coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §5.1 Pharmacodynamic properties · Version 20Document updated
Sources checked